<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of alcohol-associated steatosis and alcohol-associated cirrhosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of alcohol-associated steatosis and alcohol-associated cirrhosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of alcohol-associated steatosis and alcohol-associated cirrhosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott L Friedman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alcohol-associated liver disease (ALD) includes several liver disorders, including acute alcoholic hepatitis, alcohol associated-steatosis, and alcohol-associated cirrhosis. Patients with an alcohol intake of ≥30 grams per day (one standard drink contains 14 grams of alcohol  (<a class="graphic graphic_figure graphicRef56818" href="/z/d/graphic/56818.html" rel="external">figure 1</a>)) are at increased risk of cirrhosis, although many individuals will not develop cirrhosis despite heavy alcohol intake.</p><p>While pharmacologic options for ALD are limited, avoidance of alcohol remains the cornerstone of treatment for all patients with ALD because alcohol use is an important risk factor for disease progression. For patients with alcohol-associated cirrhosis, abstinence decreases the risk of liver-related complications. In addition, abstinence is required for placement on the liver transplantation waiting list at most transplantation centers. </p><p>This topic will discuss the management of alcohol-associated steatosis and alcohol-associated cirrhosis. The pathogenesis, clinical manifestations, and diagnosis of ALD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease"</a> and  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.) </p><p>Issues related to liver transplantation for patients with ALD are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a>.)</p><p>Treatment of alcohol use disorder (AUD) may include monitoring for alcohol use and is presented separately [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p>The clinical manifestations, diagnosis, and management of alcoholic hepatitis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/86934.html" rel="external">"Alcoholic hepatitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis"</a>.)</p><p>The clinical manifestations, diagnosis, and management of cirrhosis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p class="headingAnchor" id="H3298628510"><span class="h1">SPECTRUM OF DISEASE</span><span class="headingEndMark"> — </span>The spectrum of ALD ranges from alcohol-associated fatty liver or steatosis to alcohol-associated steatohepatitis, and eventually to alcohol-associated cirrhosis. Some patients also develop acute alcoholic hepatitis, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis"</a>.)</p><p>Patients with cirrhosis may have compensated or decompensated disease (ie, associated with complications such as hepatic encephalopathy, ascites, or variceal bleeding). In addition, the initial onset of symptoms for some patients with ALD is related to a complication of cirrhosis [<a href="#rid2">2</a>]. Factors that determine whether patients are diagnosed with ALD before developing cirrhosis are unknown. Histologic findings in different stages of ALD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis", section on 'Histologic findings'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3523803149"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Treatment goals for patients with ALD include:</p><p class="bulletIndent1"><span class="glyph">●</span>Establishing and maintaining abstinence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stabilizing liver function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cirrhosis, screening for complications (eg, esophageal varices)</p><p></p><p class="headingAnchor" id="H62577383"><span class="h2">General measures for all patients</span></p><p class="headingAnchor" id="H253571802"><span class="h3">Abstinence</span><span class="headingEndMark"> — </span>The cornerstone of managing ALD is abstinence from alcohol. Patients are referred for treatment for alcohol use disorder (AUD) to establish and maintain abstinence, and therapies for AUD, including pharmacologic and psychosocial approaches, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.) </p><p>For patients with ALD, abstinence has been associated with improved outcomes [<a href="#rid3">3-9</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Steatosis – For patients with alcohol-associated steatosis who have not progressed to cirrhosis, abstinence has been associated with rapid improvement in liver steatosis [<a href="#rid10">10-12</a>]. In a study including 26 patients with alcohol-associated steatosis diagnosed by computed tomography, abstinence was associated with improved or resolved fatty infiltration of the liver after six weeks in all patients, while two patients (8 percent) had complete resolution within one week [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1">Conversely, continued excessive alcohol consumption has been associated with progression to steatohepatitis, liver fibrosis, or cirrhosis [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis – For patients with cirrhosis, abstinence has been associated with improvements in fibrosis, in addition to lower hepatic venous pressure gradients [<a href="#rid4">4,9,14</a>]. Data have also suggested improved survival for patients with alcohol-associated cirrhosis who maintain abstinence [<a href="#rid3">3,5,6,8,14-16</a>]. As an example, in a study including 165 patients with alcohol-associated cirrhosis, abstinence was associated with higher survival rates at 1, 5, and 10 years of follow-up compared with continued alcohol use (95, 61, and 31 percent versus 63, 36, and 11 percent, respectively) [<a href="#rid5">5</a>]. Similarly, in a study including 84 patients with alcohol-associated cirrhosis, survival rates after a median of seven years were higher for those who abstained compared with persistent drinking (72 versus 44 percent) [<a href="#rid15">15</a>]. </p><p></p><p class="headingAnchor" id="H16"><span class="h3">Nutrition</span><span class="headingEndMark"> — </span>All patients with ALD are assessed for nutritional deficiencies including protein calorie malnutrition and deficiencies of vitamins, minerals, and trace elements. (See  <a class="medical medical_review" href="/z/d/html/3598.html" rel="external">"Nutritional issues in adult patients with cirrhosis"</a>.)</p><p>Nutritional assessment and supplementation in patients with AUD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use"</a>.)</p><p>For patients with ALD, we agree with society guidelines stating that the general nutrition requirements consist of eating multiple meals per day, including breakfast and a nighttime snack, to achieve the following [<a href="#rid17">17,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Total daily energy intake of 35 kcal/kg of body weight</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total daily protein intake 1.2 to 1.5 g/kg of body weight</p><p></p><p>For patients who cannot meet the daily intake requirements with their usual diet, enteral nutrition (ie, administration of liquid feeding into the intestine, by mouth or tube) is provided. Oral ingestion is the preferred method of delivery, although tube feedings (nasogastric or nasoduodenal) are used when oral intake does not meet daily requirements. </p><p>We select a specific type and quantity of enteral nutrition based on each patient's calorie and protein requirements. Some clinicians may also consult with a dietician to coordinate individualized nutrition plans for their patients.</p><p>Whether supplemental nutrition results in lower mortality is uncertain for patients with alcohol-associated cirrhosis because some trials included patients with acute alcoholic hepatitis and various nutritional interventions were used (eg, enteral nutrition, parental nutrition). As an example, in a meta-analysis of 13 trials including 761 patients with alcohol-associated cirrhosis or alcoholic hepatitis, nutritional intervention reduced mortality risk compared with no intervention (22 versus 29 percent; relative risk [RR] 0.80, 95% CI 0.64-0.99) [<a href="#rid19">19</a>].</p><p>Nutrition therapy for patients with acute alcoholic hepatitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis", section on 'Nutrition'</a>.)</p><p class="headingAnchor" id="H2186852913"><span class="h3">Immunizations</span><span class="headingEndMark"> — </span>Vaccinations for hepatitis A virus and hepatitis B virus are given to patients without serologic evidence of immunity. Additional vaccines for patients with chronic liver disease include pneumococcal vaccination and standard immunizations that are given to the general population (eg, influenza)  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 3</a>). Immunization schedules are described separately. (See  <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease", section on 'Vaccines in chronic liver disease'</a>.)</p><p class="headingAnchor" id="H3340630144"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>For all patients with ALD, clinical and laboratory monitoring includes evaluating patients for symptoms of liver disease progression (eg, jaundice, abdominal pain and distension) and obtaining liver biochemical and function tests (alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, alkaline phosphatase, and total bilirubin), and a platelet count every three months. (See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis", section on 'Laboratory tests'</a> and  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>For patients with persistently elevated liver biochemical tests, hepatology consultation is indicated. (See <a class="local">'Hepatology consultation'</a> below.)</p><p class="headingAnchor" id="H1301038642"><span class="h2">Patients with cirrhosis</span><span class="headingEndMark"> — </span>For patients with alcohol-associated cirrhosis, the management approach is similar to patients with cirrhosis from any etiology and measures for all patients include (see  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>HCC surveillance – Patients with alcohol-associated cirrhosis are at risk for developing HCC, and surveillance for HCC is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vigilance for infection – Patients with cirrhosis are at increased risk of infection, especially if they also have alcohol-associated hepatitis [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis", section on 'Infection surveillance'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for varices – Patients with alcohol-associated cirrhosis are screened for esophageal varices with upper endoscopy, and prophylactic therapy is given to those with varices at increased risk for bleeding. Screening for varices and prophylaxis against bleeding are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver transplantation evaluation for patients with decompensated cirrhosis – Most patients with decompensated cirrhosis (ie, cirrhosis and ≥1 complication such as ascites, variceal bleeding) and abstinence from alcohol are referred for evaluation at a liver transplantation center. Patient selection for and outcomes of liver transplantation in patients with alcohol-associated cirrhosis are discussed separately [<a href="#rid21">21-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a>.)</p><p></p><p>Indications for palliative care for patients with end-stage liver disease from any etiology are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease"</a>.)</p><p class="headingAnchor" id="H2781983718"><span class="h2">Hepatology consultation</span><span class="headingEndMark"> — </span>Consultation with a hepatologist should be obtained for patients with ALD who have persistently elevated liver biochemical tests (ie, ≥2 times the upper limit of normal for aminotransferases and ≥1.5 times the upper limit of normal for alkaline phosphatase). For example, patients with persistently elevated liver biochemical tests despite abstinence from alcohol may have coexisting liver disease, and the approach to evaluating patients with abnormal liver biochemical tests is discussed separately. (See <a class="local">'Abstinence'</a> above and  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H3729165441"><span class="h2">Therapies of uncertain or no benefit</span><span class="headingEndMark"> — </span>For patients with ALD, we do not use metadoxine [<a href="#rid24">24-26</a>] or silymarin (the active ingredient in milk thistle) [<a href="#rid27">27</a>] because data have not established efficacy. Thus, their role remains uncertain.</p><p>Other drugs have been studied for treating ALD, but none of them have been effective. These include <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> [<a href="#rid28">28</a>], s-adenosylmethionine [<a href="#rid29">29</a>], and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid30">30</a>]. </p><p>However, some investigational therapies are showing promise in early trials for alcohol-associated hepatitis, including epigenetic modifiers (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04563026%3Fterm%3DNCT04563026%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSxzZ%2BVrmnla6DJM7HvO8aZSIYqqsYHCIU7kRWV9IDsy76%2FssDaAY4a5W9AtsXwDly8%3D&amp;TOPIC_ID=3611" target="_blank">NCT04563026</a>), antagonists to interleukin (IL)-1b (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT03775109%3Fterm%3DNCT03775109%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwlXOsu1ESqgrSySmyan8MtbEfc%2FfJPxldYIPTvfGwjqcexdDPT9gfv%2FZ7JbFckxZ8%3D&amp;TOPIC_ID=3611" target="_blank">NCT03775109</a>), and the use of bacteriophages to eliminate bacteria that may contribute to disease pathogenesis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/87052.html" rel="external">"Management and prognosis of alcoholic hepatitis"</a>.) </p><p class="headingAnchor" id="H3140742881"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H1991980332"><span class="h2">Disease progression</span><span class="headingEndMark"> — </span>Alcohol use disorder (AUD) may lead to a spectrum of liver disease, ranging from steatosis to decompensated cirrhosis (ie, cirrhosis and ≥1 complication such as variceal bleeding, ascites). (See <a class="local">'Spectrum of disease'</a> above.)</p><p>Overall, it has been estimated that 8 to 20 percent of patients with alcohol-associated steatosis will eventually progress to cirrhosis [<a href="#rid32">32,33</a>]. While continued alcohol use is a primary risk factor for progressive ALD, other risk factors include [<a href="#rid34">34-36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting liver disease (eg, hepatitis B virus or hepatitis C virus infection)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic findings of liver inflammation (ie, neutrophils on liver biopsy specimen) [<a href="#rid37">37</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic polymorphism in the <em>PNPLA3</em> gene (also called adiponutrin) [<a href="#rid38">38,39</a>] (see  <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease"</a>)</p><p></p><p>Hepatic decompensation is common among patients with alcohol-associated cirrhosis. In a population-based study including 446 patients with alcohol-associated cirrhosis, the risk of complications (ascites, variceal bleeding, or hepatic encephalopathy) was approximately 25 percent after one year and 50 percent after five years [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H2766788746"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Studies have suggested that liver disease was a common cause of death among patients with ALD [<a href="#rid41">41-43</a>]. In a national registry study of over 23,000 patients with ALD diagnosed at a median age of 58 years, over 15,000 patients (67 percent) died during &gt;100,000 person-years of follow-up [<a href="#rid41">41</a>]. Liver disease was the primary cause of death in 7016 patients (45 percent). The 5- and 10-year mortality rates due to liver disease were 26 percent and 31 percent, respectively. These data may inform strategies to prevent liver-related mortality, in addition to emphasizing the importance of treating alcohol use disorder. (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p>Severity of ALD has been associated with increased mortality rates [<a href="#rid5">5,41</a>]. As an example, in a national registry study, patients with decompensated cirrhosis had higher mortality rates at 10 years compared with those without cirrhosis (47 versus 16 percent) [<a href="#rid41">41</a>]. In an earlier study of 122 patients with alcohol-associated cirrhosis, five-year mortality rates for patients in Child-Pugh class A, B, and C were 34, 50, and 75 percent, respectively [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'</a>.)</p><p>While alcohol-associated steatosis in the absence of cirrhosis or alcoholic hepatitis has not been associated with higher overall mortality, alcohol-associated steatosis has been associated with increased liver-related mortality [<a href="#rid33">33,44</a>]. In a national database study including 94 patients with alcohol-associated steatosis and 151 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who were followed for a median of nine years, alcohol-associated steatosis was associated with higher liver-related mortality rates compared with MASLD (36 versus 7 percent) [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H3631809027"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115541.html" rel="external">"Society guideline links: Cirrhosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116328.html" rel="external">"Society guideline links: Alcohol-associated liver disease"</a>.) </p><p class="headingAnchor" id="H39"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – The spectrum of alcohol-associated liver disease (ALD) ranges from alcohol-associated fatty liver or steatosis to alcohol-associated steatohepatitis, and eventually to alcohol-associated cirrhosis. Patients with cirrhosis may have compensated or decompensated disease (ie, associated with complications such as hepatic encephalopathy, ascites, or variceal bleeding). (See <a class="local">'Spectrum of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – Treatment goals for patients with ALD include (see <a class="local">'Goals'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Establishing and maintaining abstinence from alcohol</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stabilizing liver function</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with cirrhosis, screening for complications (eg, varices)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures for all patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abstinence</strong> – The cornerstone of managing ALD is abstinence from alcohol because abstinence has been associated with improvement in hepatic steatosis, hepatic fibrosis, and survival. (See <a class="local">'Abstinence'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment for alcohol use disorder</strong> – Patients are referred for treatment for alcohol use disorder (AUD) to establish and maintain abstinence, and therapies for AUD including pharmacologic and psychosocial approaches are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutrition</strong> – For all patients with ALD, the general nutrition requirements consist of eating multiple meals per day, including breakfast and a nighttime snack, to achieve the following (see <a class="local">'Nutrition'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Total daily energy intake of 35 kcal/kg of body weight</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Total daily protein intake 1.2 to 1.5 g/kg of body weight</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunizations</strong> – For patients with ALD, vaccinations for hepatitis A virus and hepatitis B virus are given to patients without serologic evidence of immunity. Additional vaccines for patients with chronic liver disease include pneumococcal vaccination and standard immunizations that are given to the general population (eg, influenza)  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 3</a>). (See <a class="local">'Immunizations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cirrhosis</strong> – For patients with alcohol-associated cirrhosis, the management approach is similar to patients with cirrhosis from any etiology and measures for all patients include (see <a class="local">'Patients with cirrhosis'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for hepatocellular carcinoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for esophageal varices.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with decompensated cirrhosis – Most patients with decompensated cirrhosis (ie, cirrhosis and ≥1 complication such as ascites) and abstinence from alcohol are referred for evaluation at a liver transplantation center. Patient selection for and outcomes of liver transplantation in patients with alcohol-associated cirrhosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – For patients with alcohol-associated steatosis, it has been estimated that up to 20 percent of patients will progress to cirrhosis. Risk factors for progressive disease include continued alcohol use, coexisting liver disease (eg, hepatitis C virus infection), obesity, female sex, and inflammation on liver histology. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mellinger J, Winder GS, Fernandez AC. Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research. Hepatology 2021; 73:1207.</a></li><li><a class="nounderline abstract_t">Lucey MR. Alcohol-Associated Cirrhosis. Clin Liver Dis 2019; 23:115.</a></li><li><a class="nounderline abstract_t">Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23:45.</a></li><li><a class="nounderline abstract_t">Luca A, García-Pagán JC, Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112:1284.</a></li><li><a class="nounderline abstract_t">Alvarez MA, Cirera I, Solà R, et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol 2011; 45:906.</a></li><li><a class="nounderline abstract_t">Muntaner L, Altamirano JT, Augustin S, et al. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int 2010; 30:1123.</a></li><li><a class="nounderline abstract_t">Veldt BJ, Lainé F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36:93.</a></li><li><a class="nounderline abstract_t">Senanayake SM, Niriella MA, Weerasinghe SK, et al. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes 2012; 5:663.</a></li><li><a class="nounderline abstract_t">Munsterman ID, Groefsema MM, Weijers G, et al. Biochemical Effects on the Liver of 1 Month of Alcohol Abstinence in Moderate Alcohol Consumers. Alcohol Alcohol 2018; 53:435.</a></li><li><a class="nounderline abstract_t">Tang-Barton P, Vas W, Weissman J, et al. Focal fatty liver lesions in alcoholic liver disease: a broadened spectrum of CT appearances. Gastrointest Radiol 1985; 10:133.</a></li><li><a class="nounderline abstract_t">Bashist B, Hecht HL, Harley WD. Computed tomographic demonstration of rapid changes in fatty infiltration of the liver. Radiology 1982; 142:691.</a></li><li><a class="nounderline abstract_t">Lane BP, Lieber CS. Ultrastructural alterations in human hepatocytes following ingestion of ethanol with adequate diets. Am J Pathol 1966; 49:593.</a></li><li><a class="nounderline abstract_t">Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987.</a></li><li><a class="nounderline abstract_t">Björnsson ES, Hauksson K, Sigurdardottir R, et al. Abstinence from alcohol and alcohol rehabilitation therapy in alcoholic liver disease: a population-based study. Scand J Gastroenterol 2020; 55:472.</a></li><li><a class="nounderline abstract_t">Verrill C, Markham H, Templeton A, et al. Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104:768.</a></li><li><a class="nounderline abstract_t">Hofer BS, Simbrunner B, Hartl L, et al. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clin Gastroenterol Hepatol 2023; 21:2308.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="0f6a6e7c63606969666c6a4f6a6e7c63606969666c6a216a7a">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69:154.</a></li><li><a class="nounderline abstract_t">Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol 2024; 119:30.</a></li><li><a class="nounderline abstract_t">Fialla AD, Israelsen M, Hamberg O, et al. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int 2015; 35:2072.</a></li><li><a class="nounderline abstract_t">Otero Sanchez L, Karakike E, Njimi H, et al. Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease. Hepatology 2021; 74:2714.</a></li><li><a class="nounderline abstract_t">Carrique L, Quance J, Tan A, et al. Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment With Low Rate of Relapse. Gastroenterology 2021; 161:1896.</a></li><li><a class="nounderline abstract_t">Bittermann T, Mahmud N, Abt P. Trends in Liver Transplantation for Acute Alcohol-Associated Hepatitis During the COVID-19 Pandemic in the US. JAMA Netw Open 2021; 4:e2118713.</a></li><li><a class="nounderline abstract_t">Herrick-Reynolds KM, Punchhi G, Greenberg RS, et al. Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease. JAMA Surg 2021; 156:1026.</a></li><li><a class="nounderline abstract_t">Caballería J, Parés A, Brú C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998; 28:54.</a></li><li><a class="nounderline abstract_t">Rizzo A, Breda A, Moretto F, et al. [Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine]. Clin Ter 1993; 142:243.</a></li><li><a class="nounderline abstract_t">Mao YM, Zeng MD, Li YM, et al. [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study]. Zhonghua Gan Zang Bing Za Zhi 2009; 17:213.</a></li><li><a class="nounderline abstract_t">Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100:2583.</a></li><li><a class="nounderline abstract_t">Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002; :CD002800.</a></li><li><a class="nounderline abstract_t">Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2001; :CD002235.</a></li><li><a class="nounderline abstract_t">Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005; :CD002148.</a></li><li><a class="nounderline abstract_t">Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575:505.</a></li><li><a class="nounderline abstract_t">Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141:1572.</a></li><li><a class="nounderline abstract_t">Haflidadottir S, Jonasson JG, Norland H, et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14:166.</a></li><li><a class="nounderline abstract_t">Barrio E, Tomé S, Rodríguez I, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28:131.</a></li><li><a class="nounderline abstract_t">Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257.</a></li><li><a class="nounderline abstract_t">Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35:635.</a></li><li><a class="nounderline abstract_t">Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92:208.</a></li><li><a class="nounderline abstract_t">Tian C, Stokowski RP, Kershenobich D, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42:21.</a></li><li><a class="nounderline abstract_t">Lazo M, Bilal U, Mitchell MC, et al. Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clin Gastroenterol Hepatol 2021; 19:2606.</a></li><li><a class="nounderline abstract_t">Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51:1675.</a></li><li><a class="nounderline abstract_t">Kann AE, Jepsen P, Madsen LG, et al. Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study. Lancet Gastroenterol Hepatol 2023; 8:1028.</a></li><li><a class="nounderline abstract_t">Golabi P, Paik JM, Eberly K, et al. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann Hepatol 2022; 27:100556.</a></li><li><a class="nounderline abstract_t">Hagström H, Thiele M, Roelstraete B, et al. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut 2021; 70:170.</a></li><li><a class="nounderline abstract_t">Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53:750.</a></li></ol></div><div id="topicVersionRevision">Topic 3611 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32886409" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30454826" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alcohol-Associated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640727" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9098014" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814145" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536715" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804670" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23198995" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29726886" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biochemical Effects on the Liver of 1 Month of Alcohol Abstinence in Moderate Alcohol Consumers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3996827" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Focal fatty liver lesions in alcoholic liver disease: a broadened spectrum of CT appearances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7063686" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Computed tomographic demonstration of rapid changes in fatty infiltration of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5924021" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ultrastructural alterations in human hepatocytes following ingestion of ethanol with adequate diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475591" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32233877" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abstinence from alcohol and alcohol rehabilitation therapy in alcoholic liver disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344445" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36481475" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628280" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38174913" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ACG Clinical Guideline: Alcohol-Associated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645300" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046927" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34370999" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment With Low Rate of Relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34323988" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Trends in Liver Transplantation for Acute Alcohol-Associated Hepatitis During the COVID-19 Pandemic in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379106" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537864" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482064" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19335986" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16279916" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076451" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Propylthiouracil for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687153" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : S-adenosyl-L-methionine for alcoholic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846629" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723265" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920463" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alcoholic liver disease: pathogenesis and new therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25260964" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745311" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Liver disease in heavy drinkers with and without alcohol withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586290" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A comparison of fibrosis progression in chronic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870378" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors of fibrosis in alcohol-induced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3781189" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19946271" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Variant in PNPLA3 is associated with alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32882427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20186844" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37660703" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34800721" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220902" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082596" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long term prognosis of fatty liver: risk of chronic liver disease and death.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
